

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form SC 13G/A

INDEVUS PHARMACEUTICALS INC
Form SC 13G/A
February 18, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G
(Amendment No. 3)*

Under the Securities Exchange Act of 1934

Indevus Pharmaceuticals, Inc.

Common Stock, \$.001 par value per share
(Title of Class of Securities)

February 14, 2003

(CUSIP Number: 460573108)

December 31, 2002
Date of event which requires filing

Check the appropriate box to designate the rule pursuant to which the schedule is filed:

Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filled for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes to Schedule 13G).

Page 1 of 4

CUSIP No. 460573108

13G

1. NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Lindsay A. Rosenwald, M.D.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b)

3. SEC USE ONLY

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form SC 13G/A

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5. SOLE VOTING POWER

SHARES 2,542,481

BENEFICIALLY 6. SHARED VOTING POWER

OWNED BY None

EACH 7. SOLE DISPOSITIVE POWER

REPORTING 2,542,481

PERSON 8. SHARED DISPOSITIVE POWER

WITH None

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,542,481

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.1%

12. TYPE OF REPORTING PERSON*

IN

Page 2 of 4

ITEM 1(a). NAME OF ISSUER:

Interneuron Pharmaceuticals, Inc..

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

One Ledgemount Center
99 Hayden Avenue
Lexington, MA 02421

ITEM 2(a) NAME OF PERSON FILING: Lindsay A. Rosenwald, M.D.

ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

Dr. Rosenwald's business address is 787 Seventh Avenue, 48th Floor,
New York, New York, 10019.

ITEM 2(c). CITIZENSHIP:

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form SC 13G/A

Dr. Rosenwald is a citizen of the United States of America.

ITEM 2(d). TITLE OF CLASS OF SECURITIES:

Common Stock, par value \$.001 per share.

ITEM 2(e). CUSIP NUMBER: 460573108

ITEM 3. CHECK THIS BOX IF THIS STATEMENT IS FILED PURSUANT TO
RULE 13d-1(c)

ITEM 4. OWNERSHIP

For information concerning the ownership of Common Stock of the
Company by the Reporting Person, see Items 5 through 9 and 11 of the
cover pages to this schedule 13G and footnotes thereto.

Item 4 Amount Beneficially Owned:

Each of the Reporting Persons may be deemed the beneficial owner of the
following number of Shares:

Dr. Rosenwald may be deemed the beneficial owner of 3,180,962 Shares,
which includes 638,481 shares owned by his wife, Rivki Rosenwald. Dr.
Rosenwald disclaims the beneficial ownership of the securities
beneficially owned by Rivki Rosenwald except to the extent of his
pecuniary interest therein, if any.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable

Page 3 of 4

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not Applicable

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not Applicable

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

Not Applicable

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in
a transaction having that purpose and effect.

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form SC 13G/A

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2003
New York, NY

By: /s/ Lindsay A. Rosenwald

Name: Lindsay A. Rosenwald, M.D.

Page 4 of 4